| Nov 7 |
Kura Oncology GAAP EPS of -$0.63 in-line
|
| Nov 7 |
Kura Oncology Reports Third Quarter 2024 Financial Results
|
| Nov 6 |
Kura Oncology Q3 2024 Earnings Preview
|
| Nov 5 |
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
|
| Oct 31 |
Kura Oncology to Report Third Quarter 2024 Financial Results
|
| Oct 24 |
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)
|
| Oct 23 |
Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors
|
| Oct 14 |
Kura downgraded to hold by Stifel, prefers rival Syndax
|
| Oct 9 |
Kura Oncology Inc (KURA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs
|
| Sep 30 |
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
|
